Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A.

Cancer Lett. 2014 May 1;346(2):206-16. doi: 10.1016/j.canlet.2014.01.016. Epub 2014 Jan 30. Review.


Triterpenoids as new promising anticancer drugs.

Petronelli A, Pannitteri G, Testa U.

Anticancer Drugs. 2009 Nov;20(10):880-92. doi: 10.1097/CAD.0b013e328330fd90. Review.


Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer.

Hyer ML, Shi R, Krajewska M, Meyer C, Lebedeva IV, Fisher PB, Reed JC.

Cancer Res. 2008 Apr 15;68(8):2927-33. doi: 10.1158/0008-5472.CAN-07-5759.


Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.

Deeb D, Gao X, Jiang H, Dulchavsky SA, Gautam SC.

Prostate. 2009 Jun 1;69(8):851-60. doi: 10.1002/pros.20937.


Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.

Wang YY, Yang YX, Zhe H, He ZX, Zhou SF.

Drug Des Devel Ther. 2014 Oct 23;8:2075-88. doi: 10.2147/DDDT.S68872. eCollection 2014. Review.


Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.

Wang YY, Zhe H, Zhao R.

Mol Cancer. 2014 Feb 20;13:30. doi: 10.1186/1476-4598-13-30. Review.


CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells.

Deeb D, Gao X, Dulchavsky SA, Gautam SC.

Anticancer Res. 2007 Sep-Oct;27(5A):3035-44.


Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-κB/mTOR signaling.

Gao X, Liu Y, Deeb D, Arbab AS, Guo AM, Dulchavsky SA, Gautam SC.

Anticancer Res. 2011 Nov;31(11):3673-81.


The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice.

Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K.

Cancer Prev Res (Phila). 2012 May;5(5):726-34. doi: 10.1158/1940-6207.CAPR-11-0404. Epub 2012 Mar 8.


The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent.

Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, Sporn MB, Albini A.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3139-46. Epub 2007 Dec 7.


Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies.

Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A.

Biochem Pharmacol. 2013 Jun 1;85(11):1579-87. doi: 10.1016/j.bcp.2013.03.006. Epub 2013 Mar 13.


Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.

Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW.

Mol Cancer Ther. 2007 Jan;6(1):154-62.


Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells.

Wang YY, Yang YX, Zhao R, Pan ST, Zhe H, He ZX, Duan W, Zhang X, Yang T, Qiu JX, Zhou SF.

Drug Des Devel Ther. 2015 Feb 17;9:993-1026. doi: 10.2147/DDDT.S73493. eCollection 2015.


The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling.

Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL, Andreeff M.

Cancer Res. 2007 May 1;67(9):4210-8. Erratum in: Cancer Res. 2008 Jun 15;68(12):4958.


Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids.

Venè R, Larghero P, Arena G, Sporn MB, Albini A, Tosetti F.

Cancer Res. 2008 Sep 1;68(17):6987-96. doi: 10.1158/0008-5472.CAN-07-6362.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk